Cart is empty Researchers from the University of Minnesota Medical School and College of Pharmacy have found that high costs for hepatic encephalopathy treatment in patients with end-stage liver disease are associated with decreased treatment retention for patients. The study results were recently published in Hepatology Communications.
Leave A Comment